Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes

Diabetes and Vascular Disease Research

Volumn 9, Issue 2, 2012, Pages 89-94

  Nicholls, Stephen J ^a   Uno, Kiyoko ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cardiovascular risk; Clinical trials; PPAR agonists; Therapeutic strategies

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALEGLITAZAR; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; C REACTIVE PROTEIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TESAGLITAZAR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ABDOMINAL OBESITY; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY OBSTRUCTION; DIABETIC PATIENT; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FLUID RETENTION; FRACTURE; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC REGULATION; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SIDE EFFECT; STROKE; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; PPAR ALPHA; PPAR GAMMA; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861053655     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112441477     Document Type: Review

References (80)

1. Bloomgarden ZT. Cardiovascular disease in diabetes. Diabetes Care 2010; 33: e49-e54.
2. Cornier MA, Marshall JA, Hill JO, et al. Prevention of overweight/obesity as a strategy to optimize cardiovascularhealth. Circulation 2011; 124: 840-50.
3. Plutzky J. Macrovascular effects and safety issues of therapies for type 2 diabetes. Am J Cardiol 2011; 108: 25B-32B.
4. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388-391.
5. Austin MA, Mykkanen L, Kuusisto J, et al. Prospective study of small LDLs as a risk factor for non-insulin dependentdiabetes mellitus in elderly men and women. Circulation 1995; 92: 1770-1778.
6. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 453-462. (Pubitemid 36173203)
7. Orasanu G, and Plutzky J. The pathologic continuum of diabeticvascular disease. J Am Coll Cardiol 2009; 53: S35-S42.
8. Renard CB, Kramer F, Johansson F, et al. Diabetes and diabetes- associated lipid abnormalities have distinct effects oninitiation and progression of atherosclerotic lesions. J Clin Invest 2004; 114: 659-668. (Pubitemid 39578756)
9. Rizzo M, Rini GB and Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes 2007; 115: 477-482. (Pubitemid 350056758)
10. Berger J and Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-435. (Pubitemid 34177889)
11. Adeghate E, Adem A, Hasan MY, et al. Medicinal chemistry and actions of dual and pan PPAR modulators. Open Med Chem J 2011; 5: 93-98.
12. Evans JL, Lin JJ and Goldfine ID. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: Simultaneous activation of PPARalpha, PPARgamma, and PPARdelta. Curr Diabetes Rev 2005; 1: 299-307.
13. Israelian-Konaraki Z and Reaven PD. Peroxisome proliferatoractivated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiology 2005; 103: 1-9. (Pubitemid 39541239)
14. Sprecher DL. Lipids, lipoproteins, and peroxisome proliferators activated receptor-delta. Am J Cardiol 2007; 100:n20-n24.
15. Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptoralpha in humans: No alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 46: 1319-1327. (Pubitemid 27315281)
16. Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated receptors (PPARs):Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996; 137: 354-366. (Pubitemid 26005011)
17. Hiukka A, Maranghi M, Matikainen N, et al. PPARalpha: An emerging therapeutic target in diabetic microvascular damage.Nat Rev Endocrinol 2010; 6: 454-463.
18. Arakawa R, Tamehiro N, Nishimaki-Mogami T, et al. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassettetransporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol 2005; 25: 1193-1197. (Pubitemid 40776608)
19. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7: 53-58. (Pubitemid 32095642)
20. Nakaya K, Tohyama J, Naik SU, et al. Peroxisome proliferator- activated receptor-alpha activation promotes macrophage reverse cholesterol transport through a liver X receptordependent pathway. Arterioscler Thromb Vasc Biol 2011; 31: 1276-1282.
21. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997; 272: 18779-18789. (Pubitemid 27318225)
22. Savkur RS and Miller AR. Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes. Expert OpinInvestig Drugs 2006; 15: 763-778.
23. Bassaganya-Riera J, Song R, Roberts PC, et al. PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol 2010; 23: 343-352.
24. Miyazaki Y, Matsuda M and DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002; 25: 517-523. (Pubitemid 41103346)
25. Mudaliar S and Henry RR. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med 2001; 52: 239-257. (Pubitemid 32195323)
26. Willson TM, Cobb JE, Cowan DJ, et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996; 39: 665-668.
27. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
28. Desvergne B. PPARdelta/beta: The lobbyist switching macrophage allegiance in favor of metabolism. Cell Metab 2008; 7: 467-469. (Pubitemid 351729210)
29. Weiss K, Mihaly J, Liebisch G, et al. Effect of synthetic ligands of PPAR alpha, beta/delta, gamma, RAR, RXR andLXR on the fatty acid composition of phospholipids in mice. Lipids 2011; 46: 1013-1020.
30. Shah A, Rader DJ and Millar JS. The effect of PPARalpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 2010; 210: 35-40.
31. Bilz S, Wagner S, Schmitz M, et al. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res 2004; 45: 174-185. (Pubitemid 38176628)
32. Hogue JC, Lamarche B, Deshaies Y, et al. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteinsB-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism 2008; 57: 246-254.
33. Ruel IL, Lamarche B, Mauger JF, et al. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency. Arterioscler Thromb Vasc Biol 2005; 25: 2600-2607. (Pubitemid 43732285)
34. Millar JS, Duffy D, Gadi R, et al. Potent and selective PPARalpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Thromb Vasc Biol 2009; 29: 140-146.
35. Taskinen MR, Sullivan DR, Ehnholm C, et al. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteineand creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol 2009; 29: 950-955.
36. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-910.
37. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005; 366: 1849-1861.
38. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162: 2597-2604. (Pubitemid 35453499)
39. Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005; 165: 1154-1160. (Pubitemid 40720740)
40. Tenkanen L, Manttari M, Kovanen PT, et al. Gemfibrozil in the treatment of dyslipidemia: An 18-year mortality followupof the Helsinki Heart Study. Arch Intern Med 2006; 166: 743-748.
41. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatmentwith gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995; 92: 1779-1785.
42. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial. JAMA 2001; 285: 1585-1591. (Pubitemid 32240250)
43. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for thesecondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418. (Pubitemid 29362514)
44. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.
45. Jun M, Foote C, Jicheng Lv, et al. Effects of fibrates on cardiovascular outcomes: A systematic review and metaanalysis.Lancet 2010; 375: 1875-1884.
46. Vasudevan AR and Balasubramanyam A. Thiazolidinediones: A review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 2004; 6: 850-863. (Pubitemid 40129333)
47. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: A randomized trial. JAMA 2006; 296: 2572-2581. (Pubitemid 44903861)
48. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573. (Pubitemid 351482795)
49. Davidson M, Meyer PM, Haffner S, et al. Increased highdensity lipoprotein cholesterol predicts the pioglitazonemediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 2008; 117: 2123-2130. (Pubitemid 351572171)
50. Nicholls SJ, Tuzcu EM, Wolski K, et al. Lowering the triglyceride/high- density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: Insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. J Am Coll Cardiol 2011; 57: 153-159.
51. Wilcox R, Kupfer S and Erdmann E. Effects of pioglitazoneon major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 2008; 155: 712-717.
52. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188. (Pubitemid 47403104)
53. Deeg MA and Tan MH. Pioglitazone versus rosiglitazone: Effects on lipids, lipoproteins, and apolipoproteins in headto- head randomized clinical studies. PPAR Res 2008; 2008: 520465. Epub 21 August 2008. DOI: 10.1155/2008/520465
54. Lonn EM, Gerstein HC, Sheridan P, et al. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). J Am Coll Cardiol 2009; 53: 2028-2035.
55. Sidhu JS, Kaposzta Z, Markus HS, et al. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004; 24: 930-934. (Pubitemid 38620874)
56. Yee MS, Pavitt DV, Dhanjil S, et al. The effects of rosiglitazone on atherosclerotic progression in patients with type 2 diabetes at high cardiovascular risk. Diabet Med 2010; 27: 1392-1400.
57. Bertrand OF, Poirier P, Rodes-Cabau J, et al. A multicentre, randomized, double-blind placebo-controlled trial evaluatingrosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial. Can J Cardiol 2009; 25:509-515.
58. Gerstein HC, Ratner RE, Cannon CP, et al. Effect of rosiglitazone on progression of coronary atherosclerosis in patientswith type 2 diabetes mellitus and coronary artery disease: The assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 2010; 121: 1176-1187.
59. Nissen SE and Wolski K. Rosiglitazone revisited: An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170: 1191-1201.
60. Nissen SE and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascularcauses. N Engl J Med 2007; 356: 2457-2471. (Pubitemid 46919772)
61. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis.N Engl J Med 2007; 357: 28-38. (Pubitemid 47026732)
62. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomisedcontrolled trial. Diabetologia 2012; 55: 36-45.
63. Rogue A, Spire C, Brun M, et al. Gene expression changes induced by PPAR gamma agonists in animal and human liver. PPAR Res 2010: 325183. Epub 19 October 2010.
64. Nakano K, Hasegawa G, Fukui M, et al. Effect of pioglitazone onvarious parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation highperformance liquid chromatography in newly diagnosed patients with type 2 diabetes. Endocr J 2010; 57: 423-430.
65. Marx N, Froehlich J, Siam L, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283-288. (Pubitemid 36231941)
66. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondaryprevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlledtrial. Lancet 2005; 366: 1279-1289. (Pubitemid 41416583)
67. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
68. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durabilityof rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443. (Pubitemid 44903747)
69. Lago RM, Singh PP and Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes andtype 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129-1136. (Pubitemid 47464583)
70. Loke YK, Singh S and Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: A metaanalysis. CMAJ 2009; 180: 32-39.
71. Mudaliar S, Chang AR and Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: Incidence, pathophysiology,and clinical implications. Endocr Pract 2003; 9: 406-416.
72. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256-263. (Pubitemid 38196741)
73. Scheen AJ. Combined thiazolidinedione-insulin therapy: Should we be concerned about safety? Drug Saf 2004; 27:841-856. (Pubitemid 39331683)
74. Dormandy J, Bhattacharya M and van Troostenburg deBruyn AR. Safety and tolerability of pioglitazone in highrisk patients with type 2 diabetes: An overview of data from PROactive. Drug Saf 2009; 32: 187-202.
75. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-922.
76. Hamren B, Ohman KP, Svensson MK, et al. Pharmacokineticpharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus. J Clin Pharmacol 2011. Epubahead of print.
77. Kendall DM, Rubin CJ, Mohideen P, et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levelswith muraglitazar, a dual (alpha/gamma) peroxisome proliferator- activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006; 29: 1016-1023. (Pubitemid 44115238)
78. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294: 2581-2586. (Pubitemid 41697247)
79. Henry RR, Lincoff AM, Mudaliar S, et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/gammaagonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): A phase II, randomised, dose-ranging study. Lancet 2009; 374: 126-135.
80. Cavender MA and Lincoff AM. Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: Implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs 2010; 10: 209-216.